1、2024 年 5 月 15 日，公司 2023 年年度股东大会审议通过了《关于 2023 年度利润分配预案的议案》，具体方案如下：以 2023 年 12 月 31 日总股本 202,325,700 股为基数，向全体股东每 10 股派发现金红利 2.5 元（含税），共计派 发 50,581,425.00 元，不送红股，不以资本公积金转增股本，剩余未分配利润结 转下一年度。分配预案经董事会审议后至实施前，公司股本如发生变动，将按照 分配总额不变的原则，对分配比例进行调整。 2、公司自利润分配预案披露至实施期间公司股本总额未发生变化。 3、本次实施的分派方案与股东大会审议通过的分配预案一致。 4、本次实施的分派方案距离股东大会审议通过的时间未超过两个月。 证券代码：301206 证券简称：三元生物 公告编号：2024-037 山东三元生物科技股份有限公司 2023 年年度权益分派实施公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）2023 年年度权益分 派方案已获 2024 年 5 月 15 日召开的 2023 ...

证券代码：301206 证券简称：三元生物 公告编号：2024-036 山东三元生物科技股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 现场会议时间：2024 年 5 月 15 日（星期三）15:00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为： 2024 年 5 月 15 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证券交易 所互联网投票系统的具体时间为：2024 年 5 月 15 日 9:15 至 15:00 2、会议召开地点：山东省滨州市滨北张富路 89 号三元生物公司会议室 3、会议召开方式：现场表决和网络表决相结合的方式 4、会议召集人：董事会 5、会议主持人：董事长聂在建 6、召开情况合法、合规、合章程性说明：本次会议的召集、召开与表决程 序符合《公司法》《深圳证券交易所创业板 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于山东三元生物科技股份有限公司 2023 年年度股东大会的 法律意见书 国枫律股字[2024]A0208 号 致：山东三元生物科技股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2023 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以下简 称"《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券 法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证 券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《山东三元生物 科技股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开 程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出 ...

证券代码：301206 证券简称：三元生物 公告编号：2024-034 山东三元生物科技股份有限公司 第四届董事会第二十一次会议决议公告 （一）审议通过《关于取消2023年年度股东大会部分提案的议案》。 鉴于拟聘会计师事务所近期相关事项尚待公司进一步核实，经公司与大华会 计师事务所（特殊普通合伙）协商，基于审慎原则，经研究，决定取消原定提交 2023年年度股东大会审议的第6项提案《关于续聘2024年度审计机构的议案》。除 上述取消部分提案事项外，公司2023年年度股东大会的其他提案、股权登记日、 会议召开时间、召开地点、召开方式等其他事项均保持不变。 具体内容详见公司于2024年5月8日在巨潮资讯网（www.cninfo.com.cn）披 露的《关于取消2023年年度股东大会部分提案暨2023年年度股东大会补充通知公 告》（公告编号：2024-035）。 1 / 2 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、会议召开和出席情况 山东三元生物科技股份有限公司（以下简称"公司"）第四届董事会第二十 一次会议于 2024 年 5 月 8 日上午 9:30 在 ...

证券代码：301206 证券简称：三元生物 山东三元生物科技股份有限公司 2023 年度业绩说明会投资者关系活动记录表 编号：2024-004 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □电话会议 □其他： （请文字说明其他活动内容） 参与单位名称 采用网络远程方式进行，面向全体投资者 及人员姓名 时间 2024年 4月29日15:00-17:00 地点 深圳证券交易所“互动易平台”http://irm.cninfo.com.cn“云访谈”栏目 主持人：三元生物 董事长,：聂在建 总经理：程保华 公司接待人员 董秘：高亮 ...

关于山东三元生物科技股份有限公司 中信建投证券股份有限公司 | 保荐机构名称：中信建投证券股份有限公司 | 被保荐公司简称：三元生物 | | --- | --- | | 保荐代表人姓名：陆丹君 | 联系电话：010-65608407 | | 保荐代表人姓名：陈磊 | 联系电话：010-65608268 | 四、其他事项 2023 年度持续督导跟踪报告 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 次 0 | | 2．督导公司建立健全并有效执行规章制度的情 | | | 况 | | | （1）是否督导公司建立健全规章制度（包括但 | | | 不限于防止关联方占用公司资源的制度、募集 | 是 | | 资金管理制度、内控制度、内部审计制度、关 | | | 联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月 1 次 | | （2）公司募集资金项目进展是否 ...

山东三元生物科技股份有限公司 独立董事工作制度 二〇二四年四月 | 第一章 | 总 则 | 3 | | --- | --- | --- | | 第二章 | 独立董事的任职条件和独立性 | 3 | | 第三章 | 独立董事的提名、选举和更换 | 5 | | 第四章 | 独立董事的权利和义务 | 6 | | 第五章 | 独立董事的工作保障 | 10 | | 第六章 | 独立董事的其他权利和义务 11 | | | 第七章 | 附 则 | 12 | 山东三元生物科技股份有限公司 独立董事工作制度 第一章 总 则 第一条 为进一步完善山东三元生物科技股份有限公司（以下简称"公司"） 法人治理结构，改善董事会成员结构，强化对内部董事的约束和监督机制，保护 中小股东及利益相关者的权益，促进公司的规范运作，根据《中华人民共和国公 司法》、《上市公司独立董事准则》、《深圳证券交易所创业板股票上市规则》、 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》、 《上市公司独立董事管理办法》等法律、行政法规、部门规章、规范性文件及《山 东三元生物科技股份有限公司章程》（以下简称"《公司章程》"）的规定，制订本 制 ...

Financial Performance - The company faced unprecedented challenges in the erythritol industry, leading to overcapacity and intensified competition, resulting in a decline in sales revenue and profits [4]. - The company's sales revenue and profits both experienced a year-on-year decline due to the dual impact of price and volume [4]. - The company's operating revenue for 2023 was ¥499,500,775.41, a decrease of 25.99% compared to ¥674,905,595.63 in 2022 [24]. - The net profit attributable to shareholders for 2023 was ¥58,874,449.10, down 64.03% from ¥163,686,641.34 in the previous year [24]. - The basic earnings per share for 2023 was ¥0.29, a decline of 64.63% from ¥0.82 in 2022 [24]. - The gross profit margin for erythritol was 10.50%, down from 11.61% in the previous year, while the gross profit margin for blended sweeteners was 28.24%, a decrease of 14.12% [70]. - The company reported a total operating cost of CNY 484,265,065, which represents a decrease of 16.51% from CNY 580,046,467 in 2022 [71]. - The company's revenue for 2023 was 499.50 million yuan, a decrease of 25.99% compared to the previous year, while net profit fell by 64.03% to 58.87 million yuan [156]. Cash Flow and Assets - The cash flow from operating activities for 2023 was ¥57,310,770.18, a decrease of 31.99% compared to ¥84,264,654.04 in 2022 [24]. - The total assets at the end of 2023 were ¥4,810,426,435.78, a slight decrease of 1.22% from ¥4,869,919,341.29 at the end of 2022 [24]. - The net assets attributable to shareholders at the end of 2023 were ¥4,538,022,505.51, down 1.79% from ¥4,620,776,046.41 in 2022 [24]. - The company's total assets included cash and cash equivalents of ¥108,808,330.03, down from ¥489,042,093.26 at the beginning of the year, a decrease of 7.78% [123]. Market and Industry Trends - The functional sugar market, particularly erythritol, has seen rapid growth, with China's production reaching 139,000 tons in 2022, accounting for 78.9% of global output [36]. - The price of erythritol dropped to CNY 9,500 per ton in H1 2023 due to excess capacity, but has since stabilized at CNY 10,200 per ton as of November 20, 2023 [41]. - The market for functional sugars is expected to stabilize as excess capacity is gradually eliminated, benefiting companies with high efficiency and quality products [42]. - The functional sugar industry in China is experiencing robust growth, supported by government policies and regulations aimed at promoting health and reducing sugar consumption [45]. - The market size for the sugar-free beverage industry in China is projected to reach approximately 748.9 billion CNY by 2027, with a compound annual growth rate (CAGR) of 10.80% from 2023 to 2027 [48]. Product Development and Innovation - The company is focusing on the development of functional foods and health products, which are expected to drive future growth [24]. - The company is actively pursuing new product development and technological innovation to maintain its competitive edge in the market [81]. - The company aims to enhance its product variety by developing new products such as steviol glycosides and sodium hyaluronate, which have successfully completed pilot testing [146]. - The company has developed over 20 varieties of blended sugars, including monk fruit and stevia blends, tailored to market demands [59]. - The company is currently developing a fermentation process for producing rare sugars, which is expected to diversify product offerings and create new business growth points [116]. Competitive Strategy - The company plans to maintain a pricing strategy slightly above industry peers to protect shareholder interests amid intense competition [41]. - The company emphasizes a differentiated competitive strategy focused on market demand and continuous innovation in functional sugars [57]. - The company has maintained a cost advantage in erythritol production, leveraging over ten years of experience in cost control [78]. - The company is committed to enhancing product quality and expanding market share through innovative packaging and product strategies [66]. Governance and Management - The company has established a board of directors consisting of 9 members, including 3 independent directors, complying with relevant laws and regulations [165]. - The company has a supervisory board with 3 members, including 1 employee supervisor, ensuring compliance with legal requirements [166]. - The company maintains independence from its controlling shareholders, with no unauthorized use of company funds or interference in decision-making [167]. - The company has implemented a performance evaluation and incentive mechanism for directors and senior management, aligning with its development status [168]. Research and Development - The company has increased its R&D efforts, focusing on new product development in the functional sugar sector, including high-quality stevia and sodium hyaluronate [99]. - The company's R&D investment amounted to ¥50,661,533.15 in 2023, representing 10.14% of operating revenue, a significant increase from 5.05% in 2022 [117]. - The company has achieved a target of ≥98% purity for the refined Reb M product, enhancing its market competitiveness [116]. - The company has developed core patents related to the fermentation extraction of erythritol, enhancing its production efficiency and competitiveness [91]. Customer and Supplier Relations - The company's top five distributors accounted for 27.75% of total sales revenue, with sales amounting to CNY 138,598,672.17 [74]. - The company has established long-term stable partnerships with local raw material suppliers, reducing procurement costs and transportation risks [88]. - The top five customers accounted for 36.12% of total sales, indicating a high customer concentration risk [158]. Future Outlook - The company has set a future outlook with a revenue target of 1.8 billion RMB for 2024, indicating a projected growth of 20% [190]. - The company plans to enhance market competitiveness by expanding its R&D efforts and product offerings [117]. - The company plans to increase its R&D budget by 25% in 2024, focusing on sustainable and eco-friendly product lines [190]. - The company is expanding its market presence, targeting new regions in Southeast Asia, with plans to establish two new distribution centers by mid-2024 [190].

Financial Performance - The company's revenue for Q1 2024 was CNY 191,894,599.16, representing a 65.03% increase compared to CNY 116,276,458.04 in the same period last year[4] - Net profit attributable to shareholders reached CNY 24,247,672.28, a significant increase of 210.54% from CNY 7,808,194.59 year-on-year[4] - Basic and diluted earnings per share both increased to CNY 0.12, marking a 200.00% rise from CNY 0.04 in the same quarter last year[4] - Operating profit reached CNY 25,374,529.81, up from CNY 12,876,263.21, reflecting a growth of 96.5% year-over-year[23] - The company's net profit attributable to shareholders increased to ¥769,310,662.69 from ¥745,062,990.41, showing a growth of about 3.2%[21] Cash Flow and Liquidity - The net cash flow from operating activities surged by 744.81% to CNY 22,158,704.92, up from CNY 2,622,930.65 in the previous year[9] - Cash flow from operating activities generated a net amount of CNY 22,158,704.92, compared to CNY 2,622,930.65 in Q1 2023, marking an increase of 743.5%[25] - Total cash and cash equivalents at the end of the period were CNY 95,348,055.91, down from CNY 142,378,891.60, a decrease of 32.9%[26] - The cash and cash equivalents decreased to ¥101,631,627.34 from ¥108,808,330.03, a decline of about 6.5%[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,882,280,669.13, reflecting a 1.49% increase from CNY 4,810,426,435.78 at the end of the previous year[4] - The total assets of the company as of the end of Q1 2024 were ¥4,882,280,669.13, compared to ¥4,810,426,435.78 at the beginning of the period, marking an increase of approximately 1.5%[21] - The company's total liabilities increased to ¥320,010,491.34 from ¥272,403,930.27, representing a growth of approximately 17.5%[21] Operating Costs and Expenses - The company reported a 44.95% increase in operating costs, attributed to higher sales volume and increased sales prices[8] - Total operating costs for Q1 2024 were ¥194,873,387.02, up from ¥135,685,668.54, indicating an increase of about 43.5%[22] - Research and development expenses rose by 34.31% compared to the previous year, indicating the company's commitment to enhancing competitiveness through increased investment in R&D[8] - Research and development expenses amounted to ¥15,833,077.03, compared to ¥11,788,523.18 in the prior period, reflecting a rise of approximately 34.3%[22] Shareholder Information - The total number of restricted shares held by major shareholders at the end of the period is 98,780,906 shares, with 127,969 shares released during the period[14] - The company reported a total of 5,110,900 shares held by Shanghai Tongyi Investment Management Co., Ltd., through various accounts[12] - The top 10 shareholders include significant holdings by Wang Shen and Wang Meihua, who are acting in concert[12] - The company has a total of 1,992,629 shares held by Beijing Yian Capital Management Co., Ltd., accounting for 0.98% of total share capital[13] - The company’s major shareholders include several private equity funds managed by Shenzhen Nanfang Xintai, with significant holdings reported[12] - The company has a total of 3,715,445 shares held by Shenzhen Nanfang Xintai Private Equity Fund, indicating strong institutional support[12] Financial Management Strategy - The company plans to use up to RMB 240 million of temporarily idle raised funds for cash management within 12 months, approved by the board and shareholders[15] - The company also intends to use up to RMB 100 million of temporarily idle self-owned funds for cash management, with a similar 12-month usage period[16] - The company’s financial management strategy includes rolling use of funds within the approved limits and timeframes[15] - The company’s management is authorized to make investment decisions within the specified limits for cash management[16] Other Financial Metrics - The weighted average return on net assets improved to 0.53%, up from 0.17% in the same period last year[4] - Other income decreased by 34.35% year-on-year, primarily due to a reduction in penalty income during the reporting period[8] - The company did not report any net profit from subsidiaries under common control during the period[24] - The report was not audited, which may affect the reliability of the financial data presented[27]

山东三元生物科技股份有限公司 内部控制鉴证报告 大华核字[2024]0011005634 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified PublicAccountants（Special General Partnership） 山东三元生物科技股份有限公司 内部控制鉴证报告 （截止 2023 年 12 月 31 日） 目 录 页 次 一、 内部控制鉴证报告 1-2 二、 山东三元生物科技股份有限公司 2023 年度内部 控制自我评价报告 1-11 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 内 部 控 制 鉴 证 报 告 大华核字[2024]0011005634 号 山东三元生物科技股份有限公司全体股东： 我们接受委托，鉴证了后附的山东三元生物科技股份有限公司 （以下简称三元生物公司）管理层编制的《内部控制自我评价报告》 涉及的 2023 年 12 月 31 日与财务报表相 ...